{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T14:07:32Z","timestamp":1770041252292,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Fujian Provincial Health Technology Project","award":["2022GGA022"],"award-info":[{"award-number":["2022GGA022"]}]},{"name":"the Nature Science Funding of Fujian Province","award":["2021J05049"],"award-info":[{"award-number":["2021J05049"]}]},{"name":"Joint Funds for the Innovation of Science and Technology, Fujian Province","award":["2020Y9096"],"award-info":[{"award-number":["2020Y9096"]}]},{"name":"the Joint Funds for the innovation of science and Technology, Fujian province","award":["2023Y9122"],"award-info":[{"award-number":["2023Y9122"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14142-8","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T14:32:42Z","timestamp":1745505162000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Abnormal proportions and functions of myeloid-derived suppressor cells in peripheral blood of patients with diffuse large B-cell lymphoma"],"prefix":"10.1186","volume":"25","author":[{"given":"Jingru","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shucheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanrong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaiming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maoqing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diyu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiadi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huifang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"issue":"23","key":"14142_CR1","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMc2105452","volume":"384","author":"R Lang","year":"2021","unstructured":"Lang R, Gill MJ. Diffuse large B-Cell lymphoma. N Engl J Med. 2021;384(23):2261\u20132.","journal-title":"N Engl J Med"},{"issue":"11","key":"14142_CR2","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1158\/1535-7163.MCT-22-0718","volume":"22","author":"A Schwarzer","year":"2023","unstructured":"Schwarzer A, Oliveira M, Kleppa MJ, Slattery SD, Anantha A, Cooper A, et al. Targeting aggressive B-cell lymphomas through Pharmacological activation of the mitochondrial protease OMA1. Mol Cancer Ther. 2023;22(11):1290\u2013303.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"14142_CR3","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1158\/2159-8290.CD-20-0174","volume":"10","author":"D Ennishi","year":"2020","unstructured":"Ennishi D, Hsi ED, Steidl C, Scott DW. Toward a new molecular taxonomy of diffuse large B-cell lymphoma. Cancer Discov. 2020;10(9):1267\u201381.","journal-title":"Cancer Discov"},{"issue":"16","key":"14142_CR4","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1182\/blood.2023020637","volume":"142","author":"D Belada","year":"2023","unstructured":"Belada D, Kopeckova K, Bergua Burgues JM, Stevens D, Andr\u00e9 M, Persona EP, et al. Safety and efficacy of Tafasitamab with or without Lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study. Blood. 2023;142(16):1348\u201358.","journal-title":"Blood"},{"key":"14142_CR5","doi-asserted-by":"crossref","unstructured":"Stegemann M, Denker S, Schmitt CA. DLBCL 1L-What to expect beyond R-CHOP? Cancers (Basel). 2022;14(6).","DOI":"10.3390\/cancers14061453"},{"issue":"4","key":"14142_CR6","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1158\/1078-0432.CCR-21-3140","volume":"28","author":"M Autio","year":"2022","unstructured":"Autio M, Leivonen SK, Br\u00fcck O, Karjalainen-Lindsberg ML, Pellinen T, Lepp\u00e4 S. Clinical impact of immune cells and their Spatial interactions in diffuse large B-Cell lymphoma microenvironment. Clin Cancer Res. 2022;28(4):781\u201392.","journal-title":"Clin Cancer Res"},{"key":"14142_CR7","doi-asserted-by":"crossref","unstructured":"Lin AY, Gordon LI. Discovering the fibroblastic reticular cell in the immune tumor microenvironment in lymphoma. J Clin Invest. 2023;133(13).","DOI":"10.1172\/JCI171310"},{"key":"14142_CR8","doi-asserted-by":"crossref","unstructured":"Susanibar-Adaniya S, Barta SK. 2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management. Am J Hematol. 2021;96(5):617\u2013\u200929.","DOI":"10.1002\/ajh.26151"},{"issue":"1","key":"14142_CR9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s40425-019-0674-1","volume":"7","author":"MC Apodaca","year":"2019","unstructured":"Apodaca MC, Wright AE, Riggins AM, Harris WP, Yeung RS, Yu L, et al. Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells. J Immunother Cancer. 2019;7(1):230.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"14142_CR10","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.3324\/haematol.2021.280292","volume":"107","author":"P Dong","year":"2022","unstructured":"Dong P, Chen L, Wu H, Huo J, Jiang Z, Shao Y, et al. Impaired immunosuppressive role of myeloid-derived suppressor cells in acquired aplastic anemia. Haematologica. 2022;107(12):2834\u201345.","journal-title":"Haematologica"},{"key":"14142_CR11","doi-asserted-by":"crossref","unstructured":"Cassetta L, Bruderek K, Skrzeczynska-Moncznik J, Osiecka O, Hu X, Rundgren IM et al. Differential expansion of Circulating human MDSC subsets in patients with cancer, infection and inflammation. J Immunother Cancer. 2020;8(2).","DOI":"10.1136\/jitc-2020-001223"},{"issue":"1","key":"14142_CR12","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","volume":"6","author":"K Li","year":"2021","unstructured":"Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y, et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther. 2021;6(1):362.","journal-title":"Signal Transduct Target Ther"},{"key":"14142_CR13","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.3389\/fimmu.2019.02641","volume":"10","author":"TWK Broughton","year":"2019","unstructured":"Broughton TWK, ElTanbouly MA, Schaafsma E, Deng J, Sarde A, Croteau W, et al. Defining the signature of VISTA on myeloid cell chemokine responsiveness. Front Immunol. 2019;10:2641.","journal-title":"Front Immunol"},{"key":"14142_CR14","doi-asserted-by":"crossref","unstructured":"Ma T, Renz BW, Ilmer M, Koch D, Yang Y, Werner J et al. Myeloid-Derived suppressor cells in solid tumors. Cells. 2022;11(2).","DOI":"10.3390\/cells11020310"},{"key":"14142_CR15","doi-asserted-by":"publisher","first-page":"14979","DOI":"10.1038\/ncomms14979","volume":"8","author":"M Ouzounova","year":"2017","unstructured":"Ouzounova M, Lee E, Piranlioglu R, El Andaloussi A, Kolhe R, Demirci MF, et al. Monocytic and granulocytic myeloid derived suppressor cells differentially regulate Spatiotemporal tumour plasticity during metastatic cascade. Nat Commun. 2017;8:14979.","journal-title":"Nat Commun"},{"issue":"7","key":"14142_CR16","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1182\/blood-2012-08-449413","volume":"122","author":"H Zhang","year":"2013","unstructured":"Zhang H, Maric I, DiPrima MJ, Khan J, Orentas RJ, Kaplan RN, et al. Fibrocytes represent a novel MDSC subset Circulating in patients with metastatic cancer. Blood. 2013;122(7):1105\u201313.","journal-title":"Blood"},{"issue":"72","key":"14142_CR17","doi-asserted-by":"publisher","first-page":"eabn0175","DOI":"10.1126\/sciimmunol.abn0175","volume":"7","author":"E Jou","year":"2022","unstructured":"Jou E, Rodriguez-Rodriguez N, Ferreira AF, Jolin HE, Clark PA, Sawmynaden K, et al. An innate IL-25-ILC2-MDSC axis creates a cancer-permissive microenvironment for apc mutation-driven intestinal tumorigenesis. Sci Immunol. 2022;7(72):eabn0175.","journal-title":"Sci Immunol"},{"issue":"1","key":"14142_CR18","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s12967-020-02553-z","volume":"18","author":"HH Ni","year":"2020","unstructured":"Ni HH, Zhang L, Huang H, Dai SQ, Li J. Connecting METTL3 and intratumoural CD33(+) MDSCs in predicting clinical outcome in cervical cancer. J Transl Med. 2020;18(1):393.","journal-title":"J Transl Med"},{"issue":"10","key":"14142_CR19","doi-asserted-by":"publisher","first-page":"e2106682","DOI":"10.1002\/adma.202106682","volume":"34","author":"X Lai","year":"2022","unstructured":"Lai X, Liu XL, Pan H, Zhu MH, Long M, Yuan Y, et al. Light-Triggered efficient sequential drug delivery of biomimetic nanosystem for multimodal Chemo-, antiangiogenic, and Anti-MDSC therapy in melanoma. Adv Mater. 2022;34(10):e2106682.","journal-title":"Adv Mater"},{"key":"14142_CR20","doi-asserted-by":"crossref","unstructured":"Ozbay Kurt FG, Lasser S, Arkhypov I, Utikal J, Umansky V. Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target. J Clin Invest. 2023;133(13).","DOI":"10.1172\/JCI170762"},{"issue":"1","key":"14142_CR21","doi-asserted-by":"publisher","first-page":"4074","DOI":"10.1038\/s41467-022-31723-4","volume":"13","author":"YN Li","year":"2022","unstructured":"Li YN, Wang ZW, Li F, Zhou LH, Jiang YS, Yu Y, et al. Inhibition of myeloid-derived suppressor cell arginase-1 production enhances T-cell-based immunotherapy against Cryptococcus neoformans infection. Nat Commun. 2022;13(1):4074.","journal-title":"Nat Commun"},{"issue":"1","key":"14142_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40425-019-0504-5","volume":"7","author":"JJ Miret","year":"2019","unstructured":"Miret JJ, Kirschmeier P, Koyama S, Zhu M, Li YY, Naito Y, et al. Suppression of myeloid cell arginase activity leads to therapeutic response in a NSCLC mouse model by activating Anti-Tumor immunity. J Immunother Cancer. 2019;7(1):32.","journal-title":"J Immunother Cancer"},{"issue":"19","key":"14142_CR23","doi-asserted-by":"publisher","first-page":"19242","DOI":"10.1021\/acsnano.3c05936","volume":"17","author":"S Li","year":"2023","unstructured":"Li S, Xu F, Ren X, Tan L, Fu C, Wu Q, et al. H(2)S-Reactivating antitumor immune response after microwave thermal therapy for Long-Term tumor suppression. ACS Nano. 2023;17(19):19242\u201353.","journal-title":"ACS Nano"},{"issue":"5","key":"14142_CR24","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1158\/2159-8290.CD-21-0932","volume":"12","author":"B de Ruiz-Fern\u00e1ndez","year":"2022","unstructured":"de Ruiz-Fern\u00e1ndez B, Moreno H, Valencia K, Perurena N, Ruedas P, Walle T, et al. Tumor ENPP1 (CD203a)\/Haptoglobin Axis exploits Myeloid-Derived suppressor cells to promote Post-Radiotherapy local recurrence in breast Cancer. Cancer Discov. 2022;12(5):1356\u201377.","journal-title":"Cancer Discov"},{"issue":"1","key":"14142_CR25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13287-018-1128-2","volume":"10","author":"Y Bi","year":"2019","unstructured":"Bi Y, Li J, Yang Y, Wang Q, Wang Q, Zhang X, et al. Human liver stem cells attenuate Concanavalin A-induced acute liver injury by modulating myeloid-derived suppressor cells and CD4(+) T cells in mice. Stem Cell Res Ther. 2019;10(1):22.","journal-title":"Stem Cell Res Ther"},{"issue":"12","key":"14142_CR26","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1038\/s41564-019-0541-3","volume":"4","author":"X Long","year":"2019","unstructured":"Long X, Wong CC, Tong L, Chu ESH, Ho Szeto C, Go MYY, et al. Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity. Nat Microbiol. 2019;4(12):2319\u201330.","journal-title":"Nat Microbiol"},{"key":"14142_CR27","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3389\/fimmu.2018.01310","volume":"9","author":"R Weber","year":"2018","unstructured":"Weber R, Fleming V, Hu X, Nagibin V, Groth C, Altevogt P, et al. Myeloid-Derived suppressor cells hinder the Anti-Cancer activity of immune checkpoint inhibitors. Front Immunol. 2018;9:1310.","journal-title":"Front Immunol"},{"issue":"5","key":"14142_CR28","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/bjh.13198","volume":"168","author":"A Romano","year":"2015","unstructured":"Romano A, Parrinello NL, Vetro C, Forte S, Chiarenza A, Figuera A, et al. Circulating myeloid-derived suppressor cells correlate with clinical outcome in hodgkin lymphoma patients treated up-front with a risk-adapted strategy. Br J Haematol. 2015;168(5):689\u2013700.","journal-title":"Br J Haematol"},{"issue":"8","key":"14142_CR29","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1182\/blood-2015-08-662783","volume":"128","author":"I Azzaoui","year":"2016","unstructured":"Azzaoui I, Uhel F, Rossille D, Pangault C, Dulong J, Le Priol J, et al. T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells. Blood. 2016;128(8):1081\u201392.","journal-title":"Blood"},{"issue":"9","key":"14142_CR30","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.cmet.2023.07.001","volume":"35","author":"L Wu","year":"2023","unstructured":"Wu L, Jin Y, Zhao X, Tang K, Zhao Y, Tong L, et al. Tumor aerobic Glycolysis confers immune evasion through modulating sensitivity to T cell-mediated bystander killing via TNF-\u03b1. Cell Metab. 2023;35(9):1580\u2013e969.","journal-title":"Cell Metab"},{"issue":"3","key":"14142_CR31","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.gastro.2022.11.018","volume":"164","author":"J Krug","year":"2023","unstructured":"Krug J, Rodrian G, Petter K, Yang H, Khoziainova S, Guo W, et al. N-glycosylation regulates intrinsic IFN-\u03b3 resistance in colorectal cancer: implications for immunotherapy. Gastroenterology. 2023;164(3):392\u2013e4065.","journal-title":"Gastroenterology"},{"issue":"12","key":"14142_CR32","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/s41590-019-0466-2","volume":"20","author":"FJ Barrat","year":"2019","unstructured":"Barrat FJ, Crow MK, Ivashkiv LB. Interferon target-gene expression and epigenomic signatures in health and disease. Nat Immunol. 2019;20(12):1574\u201383.","journal-title":"Nat Immunol"},{"issue":"21","key":"14142_CR33","doi-asserted-by":"publisher","first-page":"e2201258","DOI":"10.1002\/advs.202201258","volume":"9","author":"S Wang","year":"2022","unstructured":"Wang S, Shi X, Li J, Huang Q, Ji Q, Yao Y, et al. A small molecule selected from a DNA-Encoded library of natural products that binds to TNF-\u03b1 and attenuates inflammation in vivo. Adv Sci (Weinh). 2022;9(21):e2201258.","journal-title":"Adv Sci (Weinh)"},{"issue":"2","key":"14142_CR34","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.bbcan.2019.01.005","volume":"1871","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, Ma XL, Wei YQ, Wei XW. Potential roles and targeted therapy of the CXCLs\/CXCR2 axis in cancer and inflammatory diseases. Biochim Biophys Acta Rev Cancer. 2019;1871(2):289\u2013312.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"14142_CR35","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4062\/biomolther.2018.201","volume":"27","author":"S Nam","year":"2019","unstructured":"Nam S, Lee A, Lim J, Lim JS. Analysis of the expression and regulation of PD-1 protein on the surface of Myeloid-Derived suppressor cells (MDSCs). Biomol Ther (Seoul). 2019;27(1):63\u201370.","journal-title":"Biomol Ther (Seoul)"},{"key":"14142_CR36","doi-asserted-by":"publisher","first-page":"874308","DOI":"10.3389\/fimmu.2022.874308","volume":"13","author":"MM Stevenson","year":"2022","unstructured":"Stevenson MM, Valanparambil RM, Tam M. Myeloid-Derived suppressor cells: the expanding world of helminth modulation of the immune system. Front Immunol. 2022;13:874308.","journal-title":"Front Immunol"},{"issue":"9","key":"14142_CR37","first-page":"15173","volume":"8","author":"C Wu","year":"2015","unstructured":"Wu C, Wu X, Zhang X, Chai Y, Guo Q, Li L, et al. Prognostic significance of peripheral monocytic myeloid-derived suppressor cells and monocytes in patients newly diagnosed with diffuse large b-cell lymphoma. Int J Clin Exp Med. 2015;8(9):15173\u201381.","journal-title":"Int J Clin Exp Med"},{"key":"14142_CR38","doi-asserted-by":"crossref","unstructured":"Wang Z, Jiang R, Li Q, Wang H, Tao Q, Zhai Z. Elevated M-MDSCs in circulation are indicative of poor prognosis in diffuse large B-Cell lymphoma patients. J Clin Med. 2021;10(8).","DOI":"10.3390\/jcm10081768"},{"issue":"3","key":"14142_CR39","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/0008-5472.CAN-20-0617","volume":"81","author":"W Guo","year":"2021","unstructured":"Guo W, Li K, Sun B, Xu D, Tong L, Yin H, et al. Dysregulated glutamate transporter SLC1A1 propels cystine uptake via Xc(-) for glutathione synthesis in lung Cancer. Cancer Res. 2021;81(3):552\u201366.","journal-title":"Cancer Res"},{"issue":"5","key":"14142_CR40","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.cmet.2020.03.004","volume":"31","author":"H Kurniawan","year":"2020","unstructured":"Kurniawan H, Franchina DG, Guerra L, Bonetti L, Baguet LS, Grusdat M, et al. Glutathione restricts Serine metabolism to preserve regulatory T cell function. Cell Metab. 2020;31(5):920\u2013e367.","journal-title":"Cell Metab"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14142-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14142-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14142-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T14:32:47Z","timestamp":1745505167000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14142-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14142"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14142-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"17 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Review Committee of Fujian Medical University Union Hospital (2021WSJK018). And written informed consents were obtained from each patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"771"}}